Hims House

Hims House

Jonathan Stern
Country USA
Language EN
Episodes 75
Latest 18.11.2026

Hims House is a podcast for investors in Hims & Hers, the telehealth and wellness company. Hosts Jonathan Stern and Patrick Lester discuss key topics affecting the stock, including telehealth, pharma, GLP-1s, compounding, and the future of healthcare. New episodes are released weekly, with deeper analysis available on the show's Substack.

Episodes

  • 🚨 EXCLUSIVE: Max Marchione, Superpower CEO, on the peptides launch and how he's thinking about Hims
    🚨 EXCLUSIVE: Max Marchione, Superpower CEO, on the peptides launch and how he's thinking about Hims 18.11.2026 50m
    Thanks to our partners:Superpower - https://superpower.comCareValidate - https://carevalidate.com/himshouseIn episode 88, Jonathan Stern talks with Max Marchione, co-founder and CEO of Superpower, back for his third appearance on the show. Two days after HHS cleared the way for pharmacies to make BPC-157, TB-500, and four other peptides, Superpower started taking pre-orders. We get into pricing and margins, where peptide prices go by 2030, and whether Hims' California peptide factory is a real edge or a marketing play. Then we turn to Hims: what is going on with its tech and product teams, whe...
  • Hims Q3 earnings recap: "Most disappointing quarter so far" + why Brian Birnbaum is still bullish
    Hims Q3 earnings recap: "Most disappointing quarter so far" + why Brian Birnbaum is still bullish 12.11.2026 56m
    Thanks to our partners:Superpower - https://superpower.comCareValidate - https://carevalidate.com/himshouseIn episode 87, Jonathan Stern talks with Brian Birnbaum, "The Psycho Analyst," after a brutal week for the stock. We discuss Q3 earnings, which saw subscribers fall for the first time in company history. Plus, Ro disclosed $3B in annual recurring revenue, now ahead of Hims in the U.S. Brian calls Q3 the most disappointing quarter he's seen so far, but still sees Hims as a venture bet in public markets, building something Ro isn't. We debate the pace of Hims' tech and product launches, pep...
  • 🚨 BPC-157 and five other peptides just got the green light: "It's going to be a knife fight"
    🚨 BPC-157 and five other peptides just got the green light: "It's going to be a knife fight" 02.11.2026 51m
    Thanks to our partners:Superpower - https://superpower.comCareValidate - https://carevalidate.com/himshouseSubscribe to Hims House:https://himshouse.comFollow us:https://x.com/himshousehttps://x.com/jonathanrsternhttps://x.com/jefftangxIn episode 86, Jonathan Stern talks with Jeff Tang, a Y Combinator founder who sold his longevity meal prep company to Bryan Johnson and now hosts Peptide Parties in SF and LA Jeff thinks Hims is right to let Superpower and Enhanced go first, since the biggest player has the most to lose. He expects the new ban on peptide blends (like the "Wolverine Stack") to b...
  • Why Hims & Hers may be the most asymmetric opportunity in the entire stock market
    Why Hims & Hers may be the most asymmetric opportunity in the entire stock market 29.10.2026 59m
    Thanks to our partners:Superpower - https://superpower.comCareValidate - https://carevalidate.com/himshouseFollow us:https://x.com/himshousehttps://x.com/jonathanrsternhttps://x.com/TravisHoiumhttps://youtube.com/@asymmetricinvesting https://asymmetric-investing.beehiiv.com In episode 85, Jonathan Stern talks with Travis Hoium, founder of Asymmetric Investing, who started buying Hims in spring 2024 and has never sold a share. Travis explains why he calls Hims "the modern pharma company," with the doctor and pharmacy in one place and insurance left out, and why he wants operating margins near z...
  • Why payment processors treat peptides as "riskier than gambling", per gray-market peptide CEO
    Why payment processors treat peptides as "riskier than gambling", per gray-market peptide CEO 20.10.2026 55m
    Thanks to our partners:Superpower - https://superpower.comCareValidate - https://carevalidate.comFDA warning letter: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peptide-partners-llc-735063-08242026In episode 84, Jonathan Stern talks with Zak David, founder of Peptide Partners, one of the largest research-peptide sellers in the US. This is Zak's first and only interview discussing Peptide Partners' FDA warning letter! We get into why payment processors consider research peptides riskier than gambling, what advice he'd give Hims, and whether...
  • Are Peptides Coming By End Of Year?
    Are Peptides Coming By End Of Year? 15.10.2026 45m
    Thanks to our partners:Superpower - https://superpower.comCareValidate - https://carevalidate.comIn episode 83, Jonathan Stern talks with Scott Brunner, CEO of the Alliance for Pharmacy Compounding, the trade group for more than 600 compounding businesses, about the WaPo report that the administration may let pharmacies sell certain peptides before a formal rule is finished. Brunner says he thinks an announcement is "highly likely" before EOY, and he wants conditions on it: ingredients only from FDA-registered wholesalers, a clearer warning to patients, and reports of serious side effects.00:0...
  • Brazil's 2nd-largest telehealth CEO on how Hims & Hers should enter Brazil 🇧🇷
    Brazil's 2nd-largest telehealth CEO on how Hims & Hers should enter Brazil 🇧🇷 08.10.2026 52m
    Thanks to our partner: Superpower - https://superpower.comIn episode 82, Jonathan Stern talks with Abrahão Fecury, co-founder and CEO of Eles & Elas, a Brazilian telehealth company built on the Hims playbook and now at about R$4.5 million (~$1 million USD) in annual revenue, growing about +10% a month. Weight loss is about 70% of that (compounded tirzepatide) at a 54% gross margin, with hair loss and mental health smaller and more profitable. Fecury walks through cash-pay pharmacies, Meta and WhatsApp customer acquisition, and how ANVISA's summer ban on Voy changed the category. We close with...
  • Finnrick CEO on gray market peptides, fake bodega vials, and China's manufacturing prowess
    Finnrick CEO on gray market peptides, fake bodega vials, and China's manufacturing prowess 01.10.2026 40m
    Thanks to our partner:Superpower - https://superpower.com
  • OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion
    OpenLoop CEO: the peptide gray market is 2-3x bigger than analyst estimates, likely $6-8 billion 16.09.2026 30m
    Thanks to our partner:Superpower - https://superpower.comIn episode 80 of Hims House, Jonathan Stern talks with Dr. Jon Lensing, co-founder and CEO of OpenLoop, the white-label company that runs telehealth behind the scenes for other brands. Lensing started OpenLoop out of the University of Iowa's medical school and says the platform will see more than 8 million patients this year and treat more than a million a month, across 400-plus brands from telehealth companies to grocery stores, dating apps, and gyms. He said he thinks GLP-1s will become a default medication the way statins did for chol...
  • HIMS stock token hit $132 on Robinhood over the weekend due to ... $BONER coin?! 😳
    HIMS stock token hit $132 on Robinhood over the weekend due to ... $BONER coin?! 😳 03.09.2026 39m
    Thanks to our partner:Superpower - https://superpower.com🚨 WARNING: This is not a typical Hims House podcast! I wanted to do this interview because what happened on Robinhood Chain this weekend directly affected $HIMS -- and I think Hims investors should at minimum understand what happened.Jonathan Stern talks with Eric, an Ethereum OG and the world's largest $BONER holder, and Yoni, co-founder of Long.xyz, about BONER — a memecoin on Robinhood Chain paired with the $HIMS stock token. BONER reached roughly 12,000 holders in five days and helped make Hims a top-15 Robinhood stock token. Then,...
  • 🚨 THE FTC SUES HIMS & HERS -- Full breakdown with Gaston Kroub
    🚨 THE FTC SUES HIMS & HERS -- Full breakdown with Gaston Kroub 02.09.2026 53m
    Thanks to our partner:Superpower - https://superpower.comJonathan Stern talks with Gaston Kroub, founding partner of K2K Law, registered patent attorney, and Hims House's resident legal expert on his third appearance, about the FTC's July 29 federal complaint against Hims & Hers. Kroub calls the filing a public "marketing document" aimed at a quick settlement and ranks three allegation buckets: health data sharing with Meta and Snap as the most exposure, hard cancellation under ROSCA (Restore Online Shoppers' Confidence Act) second, charging before a real consultation as the least dangerous. T...
  • Bijan Salehizadeh - Eli Lilly's War on Compounded GLP-1s, Peptides, Retatrutide, and Hims vs Ro
    Bijan Salehizadeh - Eli Lilly's War on Compounded GLP-1s, Peptides, Retatrutide, and Hims vs Ro 26.08.2026 1h
    Thanks to our partner:Superpower - https://superpower.comIn episode 77, Jonathan Stern talks with Dr. Bijan Salehizadeh -- physician and managing director of NaviMed Capital, former pharma venture investor, founding investor in Auris Health. Bijan holds no position in HIMS. The conversation opens on the FDA: why Heidi Overton is "moldable clay," her 30-40% confirmation odds, and why pharma prefers interim commissioner Kyle Diamantis. They then move to Eli Lilly's multi-front war on compounded GLP-1s, the ReviveRx suit, the effort to pull semaglutide and tirzepatide off the 503B bulks list, and...
  • Enhanced Group CEO: Hot peptide summer is coming — but likely not till 2027
    Enhanced Group CEO: Hot peptide summer is coming — but likely not till 2027 07.08.2026 54m
    Thanks to our partner:Superpower - https://superpower.comMax's recent essays on peptides:https://maximilianbmartin.substack.com/p/six-peptides-one-signal-washingtonhttps://maximilianbmartin.substack.com/p/the-peptide-moment-is-here-enhancedIn episode 76 of Hims House, Jonathan Stern hosts Maximilian Martin, CEO of Enhanced Group ( $ENHA ), the newly public company behind the Enhanced Games and the Live Enhanced telehealth platform. Martin grades the inaugural games ten weeks out — 42 athletes, 21 personal bests, one world record, and $32M in contracted sponsorship — and argues the 40% stock pr...
  • 🚨 FDA committee votes "YES" on 6 of 7 peptides — here's what happens next, with Dr. Alex Tatem
    🚨 FDA committee votes "YES" on 6 of 7 peptides — here's what happens next, with Dr. Alex Tatem 27.07.2026 59m
    Thanks to our partner:Superpower - https://superpower.comIn episode 75 of Hims House, Jonathan Stern talks with Dr. Alex Tatem, a board-certified urologist who has worked with peptides for 12 years and paid his own way to Silver Spring, MD, to testify on all 7 peptides before the FDA's Pharmacy Compounding Advisory Committee. The panel overruled the FDA's own scientists and recommended six of seven for the 503A Bulks List — DSIP the lone no — and Tatem describes what the national media coverage missed: specifically, briefing documents that omitted the peptide data entirely. He explains why the...
  • The FDA peptides vote is days away. This insider expects approval
    The FDA peptides vote is days away. This insider expects approval 15.07.2026 1h 1m
    Thanks to our partner:Superpower - https://superpower.comIn episode 74, Jonathan Stern sits down with Dr. Jesse Morse, a board-certified family and sports medicine physician, longtime peptide prescriber who helped assemble safety evidence for the upcoming PCAC review. They discuss the FDA briefing recommending against adding seven peptides to the 503A bulks list and how the 2023 restrictions pushed demand into gray and black markets. Morse breaks down the 7 peptides under review -- BPC-157, TB-500, KPV, MOTS-c, DSIP, Epitalon, and Semax -- including their proposed uses, safety concerns, and hi...
  • Ryan MacDonald: Peptides could be a $30B+ market, and Hims is positioned to win meaningful share
    Ryan MacDonald: Peptides could be a $30B+ market, and Hims is positioned to win meaningful share 07.07.2026 1h
    Thanks to our partner:Superpower - https://superpower.comIn Hims House episode 73, Jonathan Stern talks with Needham’s Ryan MacDonald, the lead Hims & Hers analyst with a $35 price target and Buy rating. They break down the latest peptide news, how the FDA/PCAC process actually works, and why peptides may be more of a 2027 revenue story for major telehealth platforms like Hims. They also size the peptide opportunity, debate Hims’ potential share, and dig into GLP-1s, the Novo partnership, branded vs compounded economics, competition, valuation, short interest, insider signals, and the catalyst...
  • 🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims
    🚨 EXCLUSIVE: Hims board member David Wells on why he bought $1.2M of Hims 01.07.2026 51m
    Thanks to our partner:Superpower - https://superpower.comIn episode 72 of Hims House, Jonathan Stern interviews David Wells, Hims board member and former Netflix CFO, about his recent $1.2 million open-market purchase of Hims shares. Wells explains why he believes the company is at an inflection point after the Novo dispute and why the market may be missing the larger healthcare platform story. He discusses Hims’ mission, the broken cost and access structure of U.S. healthcare, and why he focuses more on longer-term cohorts and customer value than quarter-to-quarter CAC. The conversation cover...
  • Hedge funder Ignacio Canto on retail cults, Hims as Costco + Netflix, and why Hims has 10x upside
    Hedge funder Ignacio Canto on retail cults, Hims as Costco + Netflix, and why Hims has 10x upside 24.06.2026 1h 7m
    Thanks to our partner:Superpower - https://superpower.comIn Hims House episode 71, Jonathan Stern sits down with hedge fund manager Ignacio Canto -- founder & portfolio manager at X-Square Capital, which held over 420k Hims shares as of Q1. Canto traces his interest back years, through personal product discovery and his late father's perspective as a urologist, and frames Hims as a platform business attacking a broken, expensive, and slow healthcare system. He explains why he never considered selling through the Novo Nordisk lawsuit, then lays out the moats he cares about: network effects, dat...
  • Hedge fund manager Imran Khan bought more Hims at its most hated moment -- here's why
    Hedge fund manager Imran Khan bought more Hims at its most hated moment -- here's why 16.06.2026 53m
    Thanks to our partner:Superpower - https://superpower.comIn Hims House episode 70, Jonathan Stern sits down with hedge fund manager Imran Khan, founder and CIO of Proem Asset Management and a Hims shareholder (110,000 shares as of March 31). Khan lays out his investment framework -- long-term growth potential, execution track record -- and argues that Hims' core asset is its loyal customer base and its ability to stack new products and services on top of it, with execution as the main bear case. Drawing on his years at Snap as Chief Strategy Officer, he explains why markets overreact in both d...
  • Cremieux - Half of America could be on GLP-1s by 2030 (and why peptides are probably overhyped)
    Cremieux - Half of America could be on GLP-1s by 2030 (and why peptides are probably overhyped) 10.06.2026 48m
    In episode 69 of Hims House, Jonathan Stern welcomes back researcher and data analyst Cremieux to take stock of the GLP-1 and peptides market. Cremieux points to Epic's new EHR dashboard as the best live read on adoption, backing estimates that roughly one in eight adults are on GLP-1s and one in five have tried them -- with cost and stigma holding back uptake until semaglutide generics arrive around 2031. They also dig into the next wave of GLP-1s, spotlighting glucagon combos like servadutide and mazdutide for dramatic liver-fat reductions, plus retatrutide's standout weight-loss numbers. Cr...

Popular in

The podcast also appears in the podcast charts of these countries.